Merck VEGF-C human

VEGF-C human

recombinant, expressed in HEK 293 cells, ≥97% (SDS-PAGE)

Flt4-L, VRP

생물학적 소스

human

재조합

expressed in HEK 293 cells

태그

6-His tagged (C-terminus)

assay

≥97% (SDS-PAGE)

form

lyophilized powder

효능

0.15-0.7 μg/mL

분자량

calculated mol wt 15 kDa
observed mol wt 18-23 kDa (DTT-reduced. Protein migrates due to glycosylation. Thr 103 is the predicted N-terminus .)

포장

pkg of 10 μg

불순물

<1 EU/μg endotoxin (LAL test)

UniProt 수납 번호

P49767

배송 상태

wet ice

저장 온도

−20°C

Gene Information

human ... VEGF-C(7424)

Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP; it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parallel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.